Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical’s map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells (MSCs) in vitro.
Further, MAPCs demonstrated enhanced revascularization and new bone formation in vivo in an orthotopic defect model vs. MSCs when placed on a DBM scaffold.
As noted in the original article, this is the first study to show that MAPC plus a DBM scaffold exhibit osteogenic and angiogenic properties in an orthotopic, fibular defect model. The full study is available online.
RTI signed an agreement with Athersys in 2010 for access to MAPC technology, and announced the first human implantation of map3 in 2013. The product launched in 2014.
Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical’s map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells (MSCs) in vitro.
Further, MAPCs demonstrated enhanced revascularization and new bone...
Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical’s map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells (MSCs) in vitro.
Further, MAPCs demonstrated enhanced revascularization and new bone formation in vivo in an orthotopic defect model vs. MSCs when placed on a DBM scaffold.
As noted in the original article, this is the first study to show that MAPC plus a DBM scaffold exhibit osteogenic and angiogenic properties in an orthotopic, fibular defect model. The full study is available online.
RTI signed an agreement with Athersys in 2010 for access to MAPC technology, and announced the first human implantation of map3 in 2013. The product launched in 2014.
Copy to clipboard 
